Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757086 | 0.91 | MAOA (0.66) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5755943 | 0.88 | MAOA (0.65) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL2846668 | 0.87 | MAOA (0.71) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL2849327 | 0.87 | MAOA (0.71) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3328493 | 0.86 | CYP3A4 (0.79) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3328501 | 0.86 | CYP3A4 (0.79) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL3328495 | 0.86 | CYP3A4 (0.79) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL5757094 | 0.86 | MAOA (0.62) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL11983302 | 0.85 | MAOA (0.73) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL21999062 | 0.85 | MAOA (0.72) | MAOAMAOBCYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446403-B1 | ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050043374-A1 | Aryl substituted oxazolidinones with antibacterial activity | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1446403-A1 | ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY | AstraZeneca AB (SE) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003035648-A1 | ARYL SUBSTITUTED OXAZOLIDINONES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043374-A1 | Aryl substituted oxazolidinones with antibacterial activity | HRH2, HDHD5, HRH1 | MAOA 333/4885MAOB 221/4885CYP3A4 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.